Creative Biolabs is a well-recognized expert in the field of antibody generation and production. Especially, we have launched a series of in vitro diagnostic (IVD) antibody development services for different infections and diseases, including sepsis. Scientific progress has resulted in the discovery of novel disease biomarkers to fulfill the need for quicker, earlier, and more accurate diagnosis of sepsis. Particularly, we provide IVD antibody development services against the TIMP-1 marker.

Introduction of TIMP-1

Tissue inhibitors of metalloproteinases (TIMPs) are specific inhibitors of MMPs, which are a family of zinc-containing endoproteinases that participate in the extracellular matrix (ECM) remodeling and degradation. The balance of the extracellular largely depends on the interaction between MMPs and TIMPs. The family of TIMPs comprises four protease inhibitors: TMPI-1, TMPI-2, TMPI-3, and TMPI-4. In addition to its inhibitory role against MMPs, TMPI-1 is able to promote cell proliferation in a wide range of cell types, and may also have anti-apoptotic functions. The dysregulated activity of TIMP-1 has been implicated in cancer. Moreover, studies have pointed out that MMPs and TIMPs could be promising biomarkers for establishing prognosis during the development of sepsis.

Fig.1 TIMPs 1-4 are largely MMP inhibitors modulating the activity of soluble, matrix protein and cell associated MMPs.Fig.1 TIMPs 1-4 are largely MMP inhibitors modulating the activity of soluble, matrix protein and cell-associated MMPs. (Baker, A. H., 2002)

TIMP-1 for Sepsis Prognosis

Hoffman et al. (2006) assessed the plasma levels of TIMP-1, TIMP-2 in septic patients and they found significantly elevated levels of TMPI-1 in non-survivors compared with survivors. In addition, they established a predictive cut-off TIMP-1 serum value of 3200 ng/mL, which was associated with 4.5 times higher risk of mortality. Similar findings were reported by Lorente et al. (2009), but the difference is their cut-off plasma concentration of TIMP-1 was considerably lower than that described by Hoffman et al. Thereafter, Niño et al. (2017) quantified the levels of several markers (e.g., TIMP-1, MMP9, serum procalcitonin) in 563 septic patients. The results suggested that plasma levels of TIMP-1 should be considered as a promising prognostic biomarker in the setting of sepsis.

IVD Antibodies for TIMP-1 Marker

IVD antibodies are extensively used for disease screening, therapeutic monitoring, as well as disease prognosis and diagnosis. Creative Biolabs offers an extensive range of IVD antibody development services against a wide range of sepsis biomarkers for the diagnosis of sepsis. Our services have the following advantages:

  • Expertise: staffed by scientists with expertise and combined experience in IVD antibody development.
  • Efficiency: fast turnaround time, on-time fulfillment and delivery of orders.
  • Technical support: fully equipped facility to perform antigen & antibody conjugation, protein characterization and purification.
  • Customized-tailored solutions: work closely with you to understand your vision and find the right solution for your product.

Creative Biolabs aims to provide leading edge products and services at the best value. Besides TIMP-1, we also provide antibodies targeting other biomarkers. Contact us to discuss your projects and experience the great value of our expert services.

References

  1. Baker, A. H., (2002). “Metalloproteinase inhibitors: biological actions and therapeutic opportunities.” Journal of Cell Science, 115(19), 3719-27.
  2. Hoffmann, U., (2006). “Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of timp-1 in severe sepsis.” Scandinavian Journal of Infectious Diseases, 38(10), 867-872.
  3. Lorente, L., (2009). “Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.” Critical Care, 13(5), R158.
  4. Niño, M. E., (2017). “Timp1 and mmp9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike mmp9/timp1 ratio: multivariate model.” Plos One, 12(2), e0171191.

For Research Use Only.


Related Services:

Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2024 Creative Biolabs.
Inquiry Basket